A detailed history of Sherbrooke Park Advisers LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 5,310 shares of NBIX stock, worth $672,192. This represents 0.14% of its overall portfolio holdings.

Number of Shares
5,310
Previous 8,209 35.31%
Holding current value
$672,192
Previous $1.13 Billion 45.86%
% of portfolio
0.14%
Previous 0.2%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$114.58 - $153.15 $332,167 - $443,981
-2,899 Reduced 35.31%
5,310 $612 Million
Q2 2024

Aug 14, 2024

BUY
$130.86 - $143.19 $1.07 Million - $1.18 Million
8,209 New
8,209 $1.13 Billion

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Sherbrooke Park Advisers LLC Portfolio

Follow Sherbrooke Park Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sherbrooke Park Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sherbrooke Park Advisers LLC with notifications on news.